Company Legal Name
Latest Valuation
Founded Year
Headquarter
Medra operates an automation system that leverages artificial intelligence and robotics to execute and optimize biotech laboratory experiments. Based in San Francisco, the company addresses critical inefficiencies in pharmaceutical and biotechnology research by replacing manual, time-intensive laboratory processes with intelligent automated workflows. Medra's platform enables biotech companies to accelerate drug discovery timelines while reducing human error and operational costs. The system continuously learns and refines experimental protocols, potentially transforming how life sciences organizations conduct research and development. The company is currently focused on scaling its AI-driven laboratory automation technology to serve the growing demand for faster, more reliable biotech experimentation across the industry.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.





